

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 62

September 21, 2020

ISSUE No.  
**1607**

### IN THIS ISSUE

**In Brief: Canagliflozin and Lower Limb Amputations** .....p 152

## Important Copyright Message

### FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769

# The Medical Letter®

## on Drugs and Therapeutics

Volume 62 (Issue 1607)

September 21, 2020

Take CME Exams

### IN BRIEF

## Canagliflozin and Lower Limb Amputations

The FDA has removed a boxed warning from the labeling of products containing the sodium-glucose co-transporter 2 (SGLT2) inhibitor canagliflozin (*Invokana*, *Invokamet*, *Invokamet XR*) that described an increased risk of lower limb amputation associated with use of the drug.<sup>1</sup> Package inserts for canagliflozin products still contain a standard warning about a risk of lower limb amputation.

Canagliflozin was approved by the FDA in 2013 to improve glycemic control in patients with type 2 diabetes.<sup>2</sup> The boxed warning for amputation risk was added to its label in 2017 based on the results of two randomized, double-blind trials (CANVAS, CANVAS-R) in a total of 10,142 patients with type 2 diabetes and high cardiovascular (CV) risk. The incidence of toe, foot, or leg amputation was higher with addition of canagliflozin to standard treatment than with addition of placebo (6.3 vs 3.4 cases per 1000 patient-years).<sup>3</sup> Because these trials also demonstrated that use of canagliflozin had CV benefits, the drug was approved to reduce the risk of major adverse CV events in adults with type 2 diabetes and established CV disease in 2018.<sup>4</sup>

In 2019, based on the results of a randomized, double-blind trial (CREDESCENCE) in 4401 patients, canagliflozin was approved by the FDA to reduce the risk of end-stage kidney disease, doubling of serum creatinine, CV death, and hospitalization for heart failure in adults with type 2

diabetes and diabetic nephropathy with macroalbuminuria. The incidence of lower limb amputation in CREDESCENCE was not significantly greater with addition of canagliflozin to standard treatment than with addition of placebo (12.3 vs 11.2 cases per 1000 patient-years).<sup>4,5</sup>

Based on these recent efficacy and safety data, the FDA concluded that the risk-to-benefit profile of canagliflozin no longer warranted the inclusion of a boxed warning in the drug's label.<sup>1</sup> Patients taking canagliflozin should still be monitored for new pain, tenderness, sores, ulcers, and infections in the legs and feet.

The SGLT2 inhibitors dapagliflozin (*Farxiga*) and empagliflozin (*Jardiance*) have not been associated with an increased risk of lower limb amputation.<sup>4</sup> Ertugliflozin (*Steglatro*), a fourth SGLT2 inhibitor, has been associated with an increased risk of low-traumatic lower limb amputation in clinical trials (0.2% with 5 mg and 0.5% with 15 mg vs 0.1% with a comparator regimen)<sup>6</sup>; the drug's label contains a warning similar to that in the revised canagliflozin labeling. ■

1. FDA drug safety communication: FDA removes boxed warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). August 26, 2020. Available at: [www.fda.gov/media/141533/download](http://www.fda.gov/media/141533/download). Accessed September 10, 2020.
2. Canagliflozin (Invokana) for type 2 diabetes. *Med Lett Drugs Ther* 2013; 55:37.
3. B Neal et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med* 2017; 377:644.
4. Drugs for type 2 diabetes. *Med Lett Drugs Ther* 2019; 61:169.
5. V Perkovic et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med* 2019; 380:2295.
6. Ertugliflozin for type 2 diabetes. *Med Lett Drugs Ther* 2018; 60:70.

**PRESIDENT:** Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School  
**VICE PRESIDENT AND EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

**CONTRIBUTING EDITORS:** Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Franco M. Muggia, M.D., New York University Medical Center; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

**MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS:** Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

**FULFILLMENT AND SYSTEMS MANAGER:** Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

**EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS:** Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

#### Subscription Services

**Address:**  
The Medical Letter, Inc.  
145 Huguenot St. Ste. 312  
New Rochelle, NY 10801-7537  
[www.medicalletter.org](http://www.medicalletter.org)

**Customer Service:**  
Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
E-mail: [custserv@medicalletter.org](mailto:custserv@medicalletter.org)

**Permissions:**  
To reproduce any portion of this issue,  
please e-mail your request to:  
[permissions@medicalletter.org](mailto:permissions@medicalletter.org)

**Subscriptions (US):**  
1 year - \$159; 2 years - \$298;  
3 years - \$398. \$65 per year  
for students, interns, residents,  
and fellows in the US and Canada.  
Reprints - \$45 per issue or article

**Site License Inquiries:**  
E-mail: [SubQuote@medicalletter.org](mailto:SubQuote@medicalletter.org)  
Call: 800-211-2769  
Special rates available for bulk  
subscriptions.

Get Connected:  

Copyright 2020. ISSN 1523-2859

The Medical Letter